导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.87% | 1494/4773 |
| 近一周 | 0.82% | 40/5462 |
| 近一月 | 5.94% | 24/5421 |
| 近一季 | 5.56% | 264/5209 |
| 近半年 | 6.64% | 670/4920 |
| 近一年 | 3.74% | 1861/4366 |
| 近两年 | 42.64% | 1756/2954 |
| 近三年 | 52.16% | 511/2253 |
| 成立以来 | 86.29% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.88% 2944/4961 |
-8.42% 3882/5312 |
- - |
- - |
| 2025 | 11.29% 2752/4813 |
2.71% 1286/3635 |
12.34% 102/4076 |
-8.85% 4062/4524 |
5.83% 397/4813 |
| 2024 | 41.60% 10/3463 |
10.64% 47/2808 |
7.23% 96/3014 |
13.10% 2244/3129 |
5.53% 595/3463 |
| 2023 | -2.46% 582/2656 |
-2.57% 2016/2280 |
2.21% 155/2385 |
5.06% 101/2515 |
-6.76% 1905/2655 |
| 2022 | -4.41% 92/2207 |
2.48% 53/1919 |
-1.51% 1732/2016 |
-8.50% 205/2113 |
3.49% 685/2208 |
| 2021 | -0.08% 737/1822 |
10.73% 30/1255 |
-2.32% 1198/1330 |
-7.13% 1026/1466 |
-0.53% 1246/1822 |
| 2020 | 6.04% 876/1250 |
-13.21% 923/1028 |
3.23% 946/1067 |
7.49% 777/1164 |
10.11% 615/1184 |
| 2019 | 34.38% 404/1092 |
16.76% 662/754 |
3.11% 59/804 |
3.10% 270/850 |
8.26% 330/918 |
| 2018 | -10.78% 72/834 |
- - |
- - |
- - |
-9.47% 147/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方中证银行ETF VS. 长安沪深300非周期A(740101) |